Last updated on November 2018

Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female

Inclusion Criteria:

  1. Diagnosed with clinical or pathologic stage IIII invasive breast cancer with TXT3 tumor
  2. Has been treated with mastectomy
  3. Has undergone immediate reconstructive surgery with placement of a tissue expander or permanent implant at time of mastectomy
  4. Is a candidate for unilateral postmastectomy radiation therapy as per National Comprehensive Cancer Network (NCCN) guidelines (postmastectomy radiation therapy is indicated for most patients with positive lymph nodes at time of surgery and infrequently for selected nodenegative patients)
  5. Use of bolus is permitted, but not required
  6. Age 18

Exclusion Criteria:

  1. T4 cancer
  2. Recurrent breast cancer or history of prior breast radiation therapy
  3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and/or mental health illness that the consenting investigator feels would affect patient's ability to participate in this study
  4. Pregnant or nursing
  5. History of a different malignancy except for the following circumstances:
    • Diseasefree for at least five years and deemed by the investigator to be at low risk for recurrence of that malignancy (<5 %).
    • Cervical cancer in situ and basal cell or squamous cell carcinoma of the skin
  6. Breast cancer requiring bilateral breast/chest wall radiation therapy.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.